Biowaiver

In vivo bioavailability and/or bioequivalence investigations may be waived with a Biowaiver (not considered necessary for product approval). A dissolution test could be used as a surrogate basis for determining whether two medicinal items are equal instead of expensive and time-consuming in vivo trials. At the time, the Biowaiver was only used for pharmaceutical scale-up and post-approval adjustments (SUPAC).

  • High Solubility. High Permeability
  • Low solubility. High Permeability
  • High Solubility. Low Permeability
  • Low Solubility. Low Permeability

Related Conference of Biowaiver

September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 14-15, 2026

5th Global Summit on Pharmaceutical Research

Paris, France
January 26-27, 2027

22nd Annual Meet on Pharmaceutical Sciences

Paris, France
February 15-16, 2027

23rd Annual Congress on Pharmacology and Toxicology

Paris, France
April 08-09, 2027

21st World Drug Delivery Summit

Vienna, Austria
April 27-28, 2027

10th European Biopharma Congress

Paris, France
April 27-28, 2027

19th World Drug Delivery Summit

Paris, France

Biowaiver Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in